Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...

Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

This article delves into the approved weight loss drugs in India, their costs, and the growing market for such medications.

More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the ...

India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Initially, Dr Reddy's will focus on launching the generic semaglutide in Canada, India, Brazil, Turkey, and other emerging ...

China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for ...

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...

Willingness to try new drugs for obesity management have propelled the growth of this market, which today is almost five ...